AI assistant
Sending…
Hansa Biopharma — Major Shareholding Notification 2019
May 27, 2019
3057_iss_2019-05-27_d80c57a3-f8da-4647-adf9-29c66e0a251e.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer

Issuer Hansa Biopharma AB
Holder
Invesco Ltd.
Instrument
| Instrument | Ordinary SE0002148817 |
|---|---|
| Before the transaction | |
| Shares | 0 |
| Voting rights | 0 |
| Transaction | |
| Reason for major shareholding notification Corporate action | |
| Date | 24/05/2019 |
| Limit for number of shares | 5 % |
| Limit for number of votes | 5 % |
| After the transaction | |
| Quantity | |
| Shares | 2,705,663 |
| Directly held voting rights | 0 |
| Indirectly held voting rights | 2,705,663 |
| Percentage | |
| Directly held shares | 6.64265 % |
| Directly held voting rights | 0 % |
| Indirectly held voting rights | 6.74785 % |
Resulting distribution of total holdings
| Percentage of voting rights: |
Number of underlying shares: |
|
|---|---|---|
| Shares | 6.74785 % | 2,705,663 |
| Instruments - FITA Ch. 4, section 2, first paragraph, line 2 |
||
| Instruments - FITA Ch. 4, section 2, first paragraph, line 3 |
||
| - Physically settled | ||
| - Cash settled | ||
| Total | 6.74785 % | 2,705,663 |
| Chain of controlling companies Voting rights % Voting rights Company |
| 2,308,935 5.75842 | Invesco Advisers, Inc. | |||
|---|---|---|---|---|
| 396,728 | 0.98942 | Invesco Capital Management LLC | ||
| Group total holdings |
||||
| Voting rights | 2,705,663 | |||
| Percentage of voting rights 6.74785 |
Published
27/05/2019 11:09
Contact
| Name | Philippa Holmes | |
|---|---|---|
| Phone | 004401491417447 Email [email protected] |

[email protected] Tfn 08-408 980 37 Fax 08-24 39 25
More from Hansa Biopharma
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 1
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 1
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 27
Capital/Financing Update
2026
May 19
Capital/Financing Update
2026
May 19
Proxy Solicitation & Information Statement
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 28
Interim / Quarterly Report
2026
Apr 23
Interim / Quarterly Report
2026
Apr 23